戒烟与后续心血管疾病风险的相关性
基于Framingham心脏研究的前瞻性数据回顾性分析,纳入8770名基线无CVD的参与者,其中5308名曾吸烟者(2371名重度吸烟者≥20包年)。中位随访26.4年,共2435例首次CVD事件。与当前吸烟相比,戒烟5年内与CVD发生率显著降低相关(HR 0.61,95%CI 0.49-0.76)。与从不吸烟相比,戒烟10-15年后CVD风险仍显著升高(HR 1.25,95%CI 0.98-1.60,未达统计学显著)。
要点
- 重度吸烟者(≥20包年)戒烟5年内CVD风险显著低于继续吸烟者(HR 0.61,95%CI 0.49-0.76)。
- 与从不吸烟者相比,戒烟10-15年后CVD风险仍升高(HR 1.25,95%CI 0.98-1.60),未达统计学显著。
- 当前吸烟者CVD发生率为11.56/1000人年,戒烟5年内为6.94/1000人年,差异-4.51(95%CI -5.90至-2.77)。
- 从不吸烟者CVD发生率为5.09/1000人年,戒烟10-<15年为6.31/1000人年,差异1.27(95%CI -0.10至3.05)。
适用人群与场景
- Framingham心脏研究原始队列(1954-1958年第四次检查)和后代队列(1971-1975年首次检查)中基线无CVD的参与者,随访至2015年12月。
研究设计与关键结果
- 研究类型:前瞻性收集数据的回顾性分析;样本量8770人(原始队列3805人,后代队列4965人),平均年龄42.2岁(SD 11.8),45%男性。
- 曾吸烟者5308人,基线包年中位数17.2(IQR 7-30);重度曾吸烟者2371人(戒烟者406人[17%],当前吸烟者1965人[83%])。
- 中位随访26.4年,共2435例首次CVD事件(原始队列1612例[重度吸烟者665例];后代队列823例[重度吸烟者430例])。
- 合并队列中,与当前吸烟相比,戒烟5年内CVD发生率显著降低:当前吸烟11.56/1000人年(95%CI 10.30-12.98)vs 戒烟5年内6.94/1000人年(95%CI 5.61-8.59),差异-4.51(95%CI -5.90至-2.77);HR 0.61(95%CI 0.49-0.76)。
- 与从不吸烟相比,戒烟10-<15年后CVD风险不再显著升高:从不吸烟5.09/1000人年(95%CI 4.52-5.74)vs 戒烟10-<15年6.31/1000人年(95%CI 4.93-8.09),差异1.27(95%CI -0.10至3.05);HR 1.25(95%CI 0.98-1.60)。
证据类型、等级与局限
- 证据类型:前瞻性队列数据的回顾性分析;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对重度吸烟者(≥20包年),戒烟5年内即可显著降低CVD风险,应鼓励戒烟。
- 与从不吸烟者相比,戒烟10-15年后CVD风险仍可能升高(HR 1.25,95%CI 0.98-1.60,未达统计学显著),风险计算器仅将戒烟者视为5年风险可能低估长期风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The time course of cardiovascular disease (CVD) risk after smoking cessation is unclear. Risk calculators consider former smokers to be at risk for only 5 years.
OBJECTIVE: To evaluate the association between years since quitting smoking and incident CVD.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of prospectively collected data from Framingham Heart Study participants without baseline CVD (original cohort: attending their fourth examination in 1954-1958; offspring cohort: attending their first examination in 1971-1975) who were followed up through December 2015.
EXPOSURES: Time-updated self-reported smoking status, years since quitting, and cumulative pack-years.
MAIN OUTCOMES AND MEASURES: Incident CVD (myocardial infarction, stroke, heart failure, or cardiovascular death). Primary analyses included both cohorts (pooled) and were restricted to heavy ever smokers (≥20 pack-years).
RESULTS: The study population included 8770 individuals (original cohort: n = 3805; offspring cohort: n = 4965) with a mean age of 42.2 (SD, 11.8) years and 45% male. There were 5308 ever smokers with a median 17.2 (interquartile range, 7-30) baseline pack-years, including 2371 heavy ever smokers (406 [17%] former and 1965 [83%] current). Over 26.4 median follow-up years, 2435 first CVD events occurred (original cohort: n = 1612 [n = 665 among heavy smokers]; offspring cohort: n = 823 [n = 430 among heavy smokers]). In the pooled cohort, compared with current smoking, quitting within 5 years was associated with significantly lower rates of incident CVD (incidence rates per 1000 person-years: current smoking, 11.56 [95% CI, 10.30-12.98]; quitting within 5 years, 6.94 [95% CI, 5.61-8.59]; difference, -4.51 [95% CI, -5.90 to -2.77]) and lower risk of incident CVD (hazard ratio, 0.61; 95% CI, 0.49-0.76). Compared with never smoking, quitting smoking ceased to be significantly associated with greater CVD risk between 10 and 15 years after cessation in the pooled cohort (incidence rates per 1000 person-years: never smoking, 5.09 [95% CI, 4.52-5.74]; quitting within 10 to <15 years, 6.31 [95% CI, 4.93-8.09]; difference, 1.27 [95% CI, -0.10 to 3.05]; hazard ratio, 1.25 [95% CI, 0.98-1.60]).
CONCLUSIONS AND RELEVANCE: Among heavy smokers, smoking cessation was associated with significantly lower risk of CVD within 5 years relative to current smokers. However, relative to never smokers, former smokers' CVD risk remained significantly elevated beyond 5 years after smoking cessation.
参考来源
- Duncan MS, Freiberg MS, Greevy RA, et al. Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease. JAMA. 2019. PMID: 31429895. doi:10.1001/jama.2019.10298
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。